Metabolic medicines

MariTide (Maridebart cafraglutide)

An investigational GLP-1 agonist/GIP antagonist with one-year randomized weight-loss evidence.

Phase 2 human trial; phase 3 development

Also known as: Maridebart cafraglutide · maridebart cafraglutide

Practical use

Reviewed practical notes

Name both actions: GLP-1 agonism and GIP antagonism are different directions of action.
Keep the cohort: Results differ between participants with and without diabetes.
Compare equivalent estimates: Use the same analysis approach and follow-up period when comparing headline numbers.

Published phase 2 trial

Amgen 2026 program explanation

Overview

MariTide is maridebart cafraglutide, an antibody–peptide construct that activates GLP-1 receptors while blocking GIP receptors. That GIP antagonism distinguishes it from dual agonists such as tirzepatide and VK2735. Sharing one target does not make these medicines equivalent.

Risks and limitations

Gastrointestinal adverse events were common in phase 2. Trial tolerability varied across study conditions, and longer studies are needed to characterize uncommon harms and durability. A substantial group average is not an individual prediction.

How to read this

Amgen describes an ongoing phase 3 MARITIME program in 2026. This remains an investigational development claim. The trial measured weight and metabolic outcomes, not a guarantee of sustained benefit after treatment ends.

Research explained

52-week randomized phase 2 trial

Who was studied

592 adults: 465 with obesity without diabetes and 127 with obesity and type 2 diabetes.

What was found

In the treatment-policy analysis, mean weight change without diabetes ranged from −12.3% to −16.2%, versus −2.5% with placebo. The diabetes cohort had smaller average reductions.

What it cannot establish

Different cohorts and analysis methods must be kept distinct. A selected on-treatment estimate should not be substituted for the treatment-policy result when comparing studies.

Read the original study

Two targets do not tell you the direction of action

MariTide combines GLP-1 activation with GIP blockade. “Dual action” alone is an incomplete mechanism description, because an agonist activates a receptor and an antagonist blocks its signaling.

Supporting source

Development status remains separate from efficacy

The sponsor’s 2026 update places the compound in phase 3 development. That status is not equivalent to regulatory authorization or availability for routine treatment.